Summit Therapeutics Inc. (SMMT) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 3.55; Below-average business quality.
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a PD-1/VEGF bispecific antibody licensed from Akeso, for NSCLC and colorectal cancer globally. The company submitted a BLA in Q4 2025 with an FDA PDUFA date of November 14, 2026; it... Read more
Sell if holding. Engine safety override at $15.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 3.55; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Score 4.5/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Summit Therapeutics Inc.
Latest news
- HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $23 — benzinga May 4, 2026 neutral
- Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Port — benzinga May 3, 2026 negative
- Crude Oil Down 3%; Chevron Posts Mixed Q1 Results — benzinga May 1, 2026 neutral
- Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue — benzinga May 1, 2026 neutral
- Piper Sandler Maintains Neutral on Summit Therapeutics, Lowers Price Target to $16 — benzinga May 1, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineivonescimab10-K Item 1A: 'We depend heavily on the success of ivonescimab. If we are unable to successfully develop and commercialize ivonescimab'
- HIGHSupplierAkeso10-K Item 1A: 'We rely on the use of third parties, including Akeso, to manufacture our product candidate.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 9.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.86: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 3.55; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Prior stop was $14.74. Score 4.5/10, moderate confidence.
Take-profit target: $25.67 (+62.0% upside). Prior stop was $14.74. Stop-loss: $14.74.
Concentration risk — Pipeline: ivonescimab; Concentration risk — Supplier: Akeso; Quality below floor (1.8 < 4.0).
Summit Therapeutics Inc. trades at a P/E of N/A (forward -14.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover SMMT with a consensus score of 3.9/5. Average price target: $30.
What does Summit Therapeutics Inc. do?Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a PD-1/VEGF bispecific...
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a PD-1/VEGF bispecific antibody licensed from Akeso, for NSCLC and colorectal cancer globally. The company submitted a BLA in Q4 2025 with an FDA PDUFA date of November 14, 2026; it generates no product revenue and funds operations through equity issuances.